You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation

https://doi.org/10.1136/ebm.11.1.15

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832–9.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with heart failure, vascular disease, hypertension, or electrical cardioversion for atrial fibrillation (AF), do angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) prevent the development or recurrence of AF?

    Clinical impact ratings Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Medline and EMBASE/Excerpta Medica (from 1980), abstracts of scientific meetings (past 4 y), reference lists of relevant articles, and contact with authors of appropriate trials that did not publish AF outcomes.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) with a parallel design, published in English, that compared an ACE inhibitor or ARB with placebo, no treatment, or an alternate …

    View Full Text

    Footnotes

    • For correspondence: Dr J Healey, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. healeyj{at}hhsc.ca

    • Sources of funding: Heart and Stroke Foundation of Canada and Astra-Zeneca Canada Limited.